HYHui Yang

Hui Yang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hui Yang has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Hanwen Zhu

    West China School of Medicine, Sichuan University, Chengdu 610041, China

    1 shared publication
  • Ling Hu

    Department of Pathology & Institute of Clinical Pathology, Institute of Transplantation, Key Laboratory of Transplant Engineering and Immunology, NHC, West China Hospital, Sichuan University, Chengdu 610041, China

    1 shared publication
  • Nanjing Li

    Division of Radiotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China

    1 shared publication
  • Sinian Zheng

    Department of Pathology & Institute of Clinical Pathology, Institute of Transplantation, Key Laboratory of Transplant Engineering and Immunology, NHC, West China Hospital, Sichuan University, Chengdu 610041, China

    1 shared publication
  • Yujun Shi

    Institute of Clinical Pathology, Key Laboratory of Transplant Engineering and Immunology, NHC, West China Hospital of Sichuan University, Chengdu, 610041, China; Laboratory of Transplantation, West China Hospital of Sichuan University, Chengdu, 610041, China

    1 shared publication
  • Zhenru Wu

    Key Laboratory of Transplant Engineering and Immunology, Institute of Clinical Pathology, National Health Commission, West China Hospital, Sichuan University, Chengdu 610041, China

    1 shared publication

Latest Publications

  • Open Access

    LPCAT1 and MRPL9 Promote Hepatocellular Carcinoma Progression via AKT Phosphorylation and Define a Mitochondrial Prognostic Model

    by Hui Yang, Ziqi Zhu, Hanwen Zhu, Nanjing Li, Sinian Zheng, Ling Hu, Zhenru Wu, Yujun Shi

    Background/Objectives: Mitochondrial dysfunction plays a critical role in hepatocellular carcinoma (HCC) progression. This study aimed to identify mitochondrial-related prognostic genes and elucidate their functional mechanisms in HCC. Methods: Mitochondrial-related prognostic genes were screened from the TCGA and ICGC-LIHC cohorts. A prognostic risk model was constructed and validated in three external cohorts. Immunotherapy sensitivity between high- and low-risk groups was assessed using somatic mutation and immune infiltration analyses. Underlying molecular mechanisms were further validated through in vitro experiments in HCC cell lines. Results: Transcriptome analysis identified 15 mitochondrial-related prognostic genes, from which 10 candidates were refined using LASSO regression. Among them, LPCAT1 and MRPL9 were significantly associated with overall survival. The 2-MRG model (comprising LPCAT1 and MRPL9) demonstrated superior prognostic accuracy and better survival stratification across both internal and external cohorts. Functional enrichment analysis revealed significant metabolic dysfunction in the high-risk group. The high-risk group also exhibited a significantly higher tumor mutation burden and an enhanced predicted responsiveness to immunotherapy. In vitro, knockdown of MRPL9 or LPCAT1 inhibited the proliferation and migration of HCC cells by inducing G1/S arrest and G2/M arrest, respectively. Moreover, they also suppressed the AKT phosphorylation. Conclusions: We developed a robust 2-MRG prognostic model based on LPCAT1 and MRPL9 that effectively predicts HCC outcomes and supports individualized therapeutic decision-making. Both genes promote HCC progression by modulating the AKT phosphorylation and cell-cycle checkpoints, highlighting their potential as therapeutic targets.